Karyopharm Therapeutics Inc. (KPTI)
NASDAQ: KPTI · Real-Time Price · USD
4.390
-0.220 (-4.77%)
At close: Jul 3, 2025, 1:00 PM
4.600
+0.210 (4.78%)
After-hours: Jul 3, 2025, 2:07 PM EDT
Karyopharm Therapeutics Stock Forecast
KPTI's stock price has decreased by -63.42% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 6 analysts that cover Karyopharm Therapeutics stock have a consensus rating of "Buy" and an average price target of $48.5, which forecasts a 1004.78% increase in the stock price over the next year. The lowest target is $10 and the highest is $75.
Price Target: $48.5 (+1004.78%)
Analyst Consensus: Buy
* Price targets were last updated on May 13, 2025.
Analyst Ratings
The average analyst rating for Karyopharm Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 3 | 4 | 4 | 5 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 5 | 5 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains $34 → $33 | Buy | Maintains | $34 → $33 | +651.71% | May 13, 2025 |
| Barclays | Barclays | Buy Maintains $5 → $10 | Buy | Maintains | $5 → $10 | +127.79% | May 13, 2025 |
| Baird | Baird | Buy Maintains $54 → $42 | Buy | Maintains | $54 → $42 | +856.72% | May 13, 2025 |
| Baird | Baird | Buy Maintains $75 → $54 | Buy | Maintains | $75 → $54 | +1,130.07% | Mar 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $7 → $56 | Strong Buy | Maintains | $7 → $56 | +1,175.63% | Feb 26, 2025 |
Financial Forecast
Revenue This Year
148.27M
from 145.24M
Increased by 2.09%
Revenue Next Year
167.40M
from 148.27M
Increased by 12.90%
EPS This Year
-12.43
from -14.00
EPS Next Year
-7.67
from -12.43
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 162.8M | 198.1M | 303.3M | ||
| Avg | 148.3M | 167.4M | 218.5M | ||
| Low | 133.3M | 137.1M | 141.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 12.1% | 33.6% | 81.2% | ||
| Avg | 2.1% | 12.9% | 30.5% | ||
| Low | -8.2% | -7.5% | -15.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -7.70 | -2.91 | -0.04 | ||
| Avg | -12.43 | -7.67 | -4.59 | ||
| Low | -16.41 | -18.38 | -8.92 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.